profit from every $100 of sales.
$0$100
RadNet
$76.42+0.50% today
+4.0% in 1 year
1-year low $51.871-year high $84.48
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2020 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What RadNet sold, what it kept, and what it did with the cash.
Sales went from $1.43 billion in 2022 to $2.04 billion in 2025, with -$18.7 million of profit last year.
SalesProfit
RadNet vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| RadNet | No profit yet | ||
 Illumina | 36.8× · Expensive | ||
 Labcorp Holdings | 34.3× · Expensive | ||
 Quest Diagnostics | 28.8× · Fair price | ||
 Guardant Health | No profit yet |
AI analysis
An AI analyst reads RadNet's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| 1,072 | 1,315 | 1,430 | 1,617 | 1,830 | 2,040 | |
| – | – | 166 | 221 | 249 | 235 | |
| – | – | 50 | 93 | 111 | 83 | |
| – | – | 279 | 293 | 323 | 314 | |
| -15 | 25 | 11 | 3 | 3 | -19 | |
| -0.29 | 0.46 | 0.17 | 0.05 | 0.04 | -0.25 | |
| – | – | 11.6% | 13.7% | 13.6% | 11.5% | |
| – | – | 3.5% | 5.8% | 6.1% | 4.1% | |
| -1.4% | 1.9% | 0.7% | 0.2% | 0.2% | -0.9% |
Balance sheet
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Total assets | 1,787 | 2,058 | 2,434 | 2,690 | 3,287 | 3,759 |
| Cash | 102 | 135 | 128 | 343 | 740 | 767 |
| Total debt | 1,182 | 1,398 | 1,513 | 1,491 | 1,729 | 1,859 |
| Total liabilities | 1,528 | 1,712 | 1,942 | 1,877 | 2,153 | 2,403 |
| 166 | 229 | 333 | 631 | 902 | 1,090 | |
| 51 | 53 | 57 | 65 | 75 | 75 | |
| 2.6% | 5.2% | 4.0% | 3.8% | 3.7% | 2.7% | |
| -9.0% | 10.8% | 3.2% | 0.5% | 0.3% | -1.7% |
Cash flow
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| 234 | 149 | 146 | 221 | 233 | 299 | |
| – | – | 119 | 177 | 188 | 213 | |
| – | – | 27 | 44 | 45 | 86 | |
| Dividends paid | – | – | – | – | – | – |
| – | – | – | – | – | – | |
| 12 | 25 | 24 | 27 | 30 | 55 |
Valuation
- –
- 123.8×
- –
- 3.9×
- 3.0×
- 70.4×
- 22.7×
- 1.4%
- -0.3%
- 0.0%
Profitability
- 11.5%
- 4.1%
- -0.9%
- 14.9%
- 1.6%
- 0.3%
- -1.4%
- -0.4%
- 2.4%
- –
Growth
- +13.7%
- –
- +90.4%
- –
- +9.4%
Financial health
- 4.6×
- 1.79
- 49.8%
- 1.1×
- 1.17
- 1.17
- 0.55
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 37%of 952
Bottom 34%of 884
Top 40%of 886
Top 49%of 987
What analysts expect
- Average price target
- $92.00
- Range
- $90.00 – $95.00
- 1 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 11, 2026 | -0.28 | -0.14 | −100.0% |
| Mar 2, 2026 | 0.23 | 0.19 | +21.1% |
| Nov 9, 2025 | 0.20 | 0.22 | −10.3% |
| Aug 10, 2025 | 0.31 | 0.17 | +82.4% |
| May 11, 2025 | -0.35 | -0.17 | −105.9% |
| Feb 27, 2025 | 0.22 | 0.21 | +4.8% |
| Nov 10, 2024 | 0.18 | 0.14 | +32.5% |
| Aug 7, 2024 | 0.16 | 0.16 | +0.0% |
News
3 Reasons to avoid RDNT and 1 stock to buy insteadYahoo Finance · Oct 28, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
8No pass
Benjamin Graham
13No pass
Philip Fisher
21No pass
Peter Lynch
40No pass
Joel Greenblatt
0No pass
Charlie Munger
6No pass
Terry Smith
11No pass
Questions about RadNet
Is RadNet a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the RadNet AI analysis
What does RadNet do?
RadNet, Inc., together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. It is in Medical - Diagnostics & Research, based in Los Angeles, CA, United States, with 11,000 employees.
Does RadNet pay a dividend?
No. RadNet does not pay a dividend at the moment.
Is RadNet stock halal?
Questionable. RadNet sits in a grey zone: its debt is 31% of its market value, between 30% and 33%. How we check
How has RadNet stock done over the past year?
Up 4.0% over the past twelve months, to $76.42. It traded between $51.87 and $84.48 and is 9.5% below its high.
Who are RadNet's competitors?
The largest listed companies in the same industry are Illumina, Labcorp Holdings, Quest Diagnostics and Guardant Health. The peers table on this page compares their profit, growth and price with RadNet's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.